Consistent with this, patients with metastatic KRAS+/TP53+ NSCLC did not respond to the phase 1 trial therapy well, with a median PFS of 2 months (95% CI, 1.2-2.8 months), which was significantly worse than that in KRAS+/TP53-, KRAS-/TP53+, and KRAS-/TP53- patients (3.7 months; 95% CI, 2.5-4.9 months). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.